focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
A leading WHO covid envoy says the virus is nowhere near finished and getting much worse.
https://news.sky.com/story/covid-news-live-england-lifts-all-coronavirus-restrictions-on-19-july-but-minister-says-one-never-knows-if-its-irreversible-12354097
Hi All,
I’ve had a watch of Boris’s press conference and questions placed by media and members of the public afterwards. Some concerning issues have come to light (well for me personally and each to their own – opinion that is)
I cannot believe that the UK Govt is being so cavalier with opening up. Why?;
1. The UK is likely never to reach Herd Immunity (as are many other nations). The WHO requires at least 80% through to 95% vaccination of a population to reach the goal (https://www.who.int/news-room/q-a-detail/herd-immunity-lockdowns-and-covid-19).
There are a large number of people in the UK who cannot have the vaccine and will require shielding - who knows until when – hardly freedom day for these poor souls
2. An estimated 15% will refuse the virus out of being an antivaxxer, mistrust of the science, conspiracy theories etc.
3. Reported by Chris Witty at the press conference in response to a question from the Times, having the vaccine does not stop people reacquiring the virus and transmitting it to someone else. He actually said ‘there are no absolute figures on this for the Delta variant but the Alpha variant had a roughly decreasing transmission rate of approximately 50%.
4. The vaccine efficacy against Delta (still not confirmed with absolute numbers is as follows – 1 jab only gives 32-38% protection and 2 jabs only gives 78-80% protection, therefore still a real chance with lifting restrictions that covid (delta) will attack the population hard. This is without considering the new Delta+, Epsilon and Lambda variants that have reportedly arrived in the UK. Each new variant is again reported to be more infectious than the last.
5. I have the distinct feeling that based on the 15% (9.75M) who won’t have the vaccine and the population that will still need shielding that the UK is probably reaching its maximum amount of vaccinated population (approx 48 Million (1 jab) and 35Million 2 jabs)– and was the reported vaccination progress in the press conference). Hence, the date for lifting restrictions not really being a concern as they have vaccinated as many as want it or can have it.
6. So that’s 50% of the population with 2 jabs and achieving at best 80% protection, who are still passing it on once reacquiring it – Herd Immunity?????
Therefore opening up now and relying on the population to do the responsible thing (in pubs, nightclubs, sporting fixtures, etc etc) is absolutely crazy, I’m expecting to see cases, isolations, hospitalisation and deaths off the charts in the weeks/months which will inevitably lead to another hard lockdown and complete ‘U turn’ by UK Govt. (hope I’m wrong)
The need for covid therapeutics is literally right now.
GLA
Hi All
The silence from the company is truly ‘deafening’
On the website there is a page dedicated to our SDC-1801 in covid (www.Sareum.com/discovery/tyk2jak1-COVID-19/)
I would have thought this would have been updated by now indicating our completion of the UKRI funded experiments and the consideration we are superior to dexamethasone and similar to baricitinib.
Links to the success are on the website but why would you not update the specific page.
They must be busy eh!!!
GLA
Hi All
So Boris will this afternoon set out his plan to either lift all restrictions or opt to have some remaining next week.
He may also use this speech to mention again his intention for covid therapeutics in light of the increasing delta cases.
News must be getting close now
GLA
Great Find Bobbler
It’s looks like TYK2 really excited Prof Baillie......*they now have enough preclinical data on how this JAK signalling works to be able to proceed straight into large scale trials*
Bring on SDC-1801 into AGILE/Recovery and put in the no.1 position for covid therapeutics ahead of dexamethasone.
GLA
Boris specifically stated a UK based company with UK manufacturing.
I’m sure there will be others (Merck and Pfizer) but it really isn’t anything to worry about. There are more than a few vaccines.
It may turn out that ours doesn’t work but that said all the indications so far suggest otherwise.
GLA
Hi All
I’ve been reading the RNSs again on the run up to the release of the 01 July RNS and confirmation that SDC-1801 is considered superior to dexamethasone.
The earlier RNSs in June stated ‘on schedule to finish end of June with results shortly after’ or words to that affect.
If you refer to the UKRI website it stated the POC ran through to May 2021.
Therefore, IMHO the company, UKRI, antivirals taskforce and UK cabinet office have known the results for sometime. My opinion is based on many snippets of information:
1. SAR release the results 01 July, the day after end of June stating superior to dexamethasone. The RNS would have been through drafting and approval for at least a week (or more) before.
2. UKRI were confirmed to have been witnessing and reporting on the POC progress.
3. Boris announced 21 April the covid pill by Autumn.
He wouldn’t make such a bold statement without credible knowledge/data. He was reading a prepared speech meaning several government advisers/scientists involved in preparing it.
4. Boris announced forming of the antivirals taskforce headed by his leading scientists on 21 April
5. Parker’s tweet ‘major development’ 22 April. This was caveated at the time with ‘if successful’, to my mind being Superior to the drug that reported to save 1 million lives in a short period is the success!
6. The £2.4 million investment by the unnamed HNWI.
7. Items 2 and 3 were before the onset of Delta cases now growing exponentially (doubling every 11 days) and likely bypassing the vaccine antibodies.
I believe there have been very detailed negotiations with SAR on trial design, manufacturing, commercial roll out and PR/media preparations. The silence from SAR is deafening since 01 July - no proactive investors video interviews, no ‘wink wink’ tweets and no broker notes......all very strange considering we have ground breaking/blockbuster/transformational news that we are now SUPERIOR to dexamethasone! You think this would be being broadcast on every available outlet SAR have access to???
As mentioned previously, it would be good to see for ourselves the results of the data, are these being withheld as they now form elements of an NDA??
GLA
Hi All
Some healthy debate over the weekend on what is a very sensitive subject. I’m not an antivaxer but if you take time to search my posts, I previously posted a link from a Lancet article about how the vaccines are tested for efficacy and effectiveness. The article suggests that the pharmaceutical companies ‘cherry picked’ data to show the best results during testing. Apparently, there is a formula that is widely accepted to show efficacy and effectiveness plus the total number of people needed to be vaccinated for a roll out to reach ‘herd immunity’.
However, the pharma’s only chose one element of the vaccine data and sowed that number to mainstream media. The lancet questioned this as likely a little disappointing. The actual complete efficacy and effectiveness after applying the formula is much lower and way below the 50% benchmark set by the FDA.
Like I said I’m not against the vaccines but more the too fast roll out - in fact all the vaccines are still labelled ‘experimental’. The governments of the world had little choice when faced with rising deaths, crippled economies and lockdowns - but you would have thought that they would have accepted liability??
Good luck ENGLAND
Oh dear - I said earlier this week that if the news was good it would have been known months ago.......
*Shares in Evgen Pharma PLC fell sharply Friday after results from an interim assessment of a late-stage clinical trial to assess its lead asset as treatment for acute respiratory infections, including suspected Covid-19 infections, disappointed.
The London-listed drug-development company said recruitment for the Phase 2/3 trial of its SFX-01 product will be halted after an independent data management committee concluded analyses of interim safety and efficacy data didn't meet the interim futility hurdle required to continue the study.*
https://www.marketwatch.com/story/evgen-pharma-shares-plunge-after-clinical-trial-disappoints-271625815517
Bodes well for us and AGILE entry
GLA
I’m not too concerned with competitors in the JAK inhibitor market. We know we are ‘cleaner’ than some of the others. Further not all competitors will be targeting the same indications.
The market is expected to reach the value of $64.9Bn by 2027. (https://transparencymarketresearch.com/kinase-inhibitors.html)
As we know, in our individual patents fir SDC-1801 and SDC-1802 we have listed over 30 autoimmune conditions and over 55 cancers that can be targeted.
GLA
Hi Citizen - great post. Good to see 23andMe mentioned again in the Bloomberg article. All is falling into place. You may recall a post of mine from 2 weeks ago, were I said I hope msm get hold of this and start putting the word out. Hats off to Nature but we need more mainstream.
IMO - I’m expecting some news from Boris either on or before the 12 July so he can frame up expectations further for releasing restrictions on the 19 July - he needs a ‘good news’ story for covid and IMHO the Euros won’t cut it.......
GLA
Japan declares a COVID state of emergency for Tokyo that will run through the city’s hosting of the Olympics and mulls banning all spectators.
https://aje.io/kgbuva
Al jazeera news
Hi Citizen
Section 5 is also very interesting, I’m sure this is also being looked into by 23andme in association with GSK and funded by Richard Branson (Thoth has been posting also).
If these bio markers can be identified in genes then it’s gives a good prediction on the likelihood of individuals developing conditions and then there prognosis for treatments with targeted drugs.......next generation diagnosis and medical treatment/intervention.
GLA